賽生藥業(6600.HK)一度漲44% 旗下日達仙獲納入新冠治療用藥

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

賽生藥業(6600.HK)一度漲44% 旗下日達仙獲納入新冠治療用藥

格隆匯 12-06 10:07

格隆匯12月6日丨賽生藥業(6600.HK)盤中一度漲超44%至12港元。該公司旗下核心自研產品日達仙已被納入國家衞健委、中華醫學會等專業協會發布的治療指南，用於膿毒症、胰腺癌、肝癌、COVID-19以及胃癌等的治療。

賽生藥業(06600.HK)

Relevant Stocks

賽生藥業(06600.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

賽生藥業(6600.HK)一度漲44% 旗下日達仙獲納入新冠治療用藥

Services

About Us

Agreement Statement